$SUJA

Suja Life Reports First Quarter 2026 Financial Results

Suja Life (NASDAQ: SUJA) reported first-quarter 2026 net sales of $107.1 million, up 22.5% year over year from $87.4 million. Adjusted EBITDA rose 66.3% to $25.0 million, with margin expanding to 23.4%. Net income was $7.7 million versus a prior-year net loss. The company initiated 2026 guidance: net sales $367–$371 million and Adjusted EBITDA $70–$72 million.

Original reporting
Published Jun 9, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 9:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Suja Life Reports First Quarter 2026 Financial Results — source image
Decision brief

The 30-second read

$SUJABullishMed
01

Why it matters

The print highlights accelerating net sales (+22.5% YoY) and a sharp jump in Adjusted EBITDA (+66.3% YoY), alongside gross margin expansion and a shift to positive net income. The FY2026 guidance provides a concrete growth and profitability roadmap (net sales $367–$371M; Adjusted EBITDA $70–$72M).

02

Market read

Traders can update forward models using the explicit FY2026 ranges and assess whether Q1 margin expansion and EBITDA leverage are sustainable.

03

What to watch

SG&A as a % of sales rose (35.3% vs 41.3% prior year, but freight increased), and the company notes inability to reconcile forward Adjusted EBITDA to GAAP net income, leaving GAAP earnings visibility limited.

Relevance 9/10Novelty 9/10Timing: today’s Q1 results and same-day FY2026 outlook

Background

Suja Life began trading on Nasdaq under SUJA on May 7, 2026 and completed its IPO on May 8, 2026; this is its first-quarter post-IPO financial update with an FY2026 outlook.

Company-level read

Ticker impact

$SUJABullishHigh confidence
Context

Suja Life reports Q1 2026 results and initiates FY2026 outlook, including net sales, Adjusted EBITDA, and full-year guidance.

Expected impact

Likely positive near-term bias as guidance provides a fresh valuation anchor for a newly public name.

Evidence & confidence

The article contains a full Q1 financial print (sales, gross margin, net income, Adjusted EBITDA) plus explicit FY2026 net sales and Adjusted EBITDA ranges, which are direct inputs to forward estimates and positioning.

Market effects

Reinforces demand/read-through for “better-for-you” natural beverage brands with functional benefits and clean ingredients.

No specific regional spillover beyond US retail distribution performance.

Limited; primarily US consumer packaged beverages and domestic distribution.

Counterpoint

Adjusted EBITDA outperformance may be sensitive to promotional intensity, freight costs, and shipment timing rather than durable underlying demand.

Key entities

  • Suja Life, Inc.

    Reports Q1 2026 financial results and initiates FY2026 outlook; newly public on Nasdaq (SUJA).

  • Maria Stipp

    CEO quoted on Q1 performance drivers and growth positioning.

Related articles

$SUJAMed

Suja Defies Grocery Slowdown With Double-Digit Sales Growth in Q2

Suja Life, Inc. (Nasdaq: SUJA) reported Q2 net sales up 11.6% year over year to $83.9 million, citing volume growth and improved distribution. Gross profit increased 9.9% to $39.2 million, or 46.7% of sales. The company raised its 2026 outlook to $360 to $369 million net sales from $326.6 million in 2025.

$SUJAMed

SUJA LIFE, INC. (SUJA): Results of Operations and Financial Condition

SUJA LIFE, INC. (SUJA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sujalifeq22026earningsrele.htm EX-99.1 Document Suja Life Reports Second Quarter 2026 Financial Results Net sales increased 11.6% year-over-year to $83.9 million Updates fiscal year 2026 outlook OCEANSIDE, CA, August 4, 2026 – Suja Life, Inc. (NASDAQ: SUJA) (“Suja Life,

$SUJAMed

Suja Life (NASDAQ:SUJA) Upgraded to “Strong-Buy” at Evercore

Evercore upgraded Suja Life (NASDAQ:SUJA) to a “strong-buy” rating in a Monday research note, according to Zacks.com. Other firms also initiated coverage: Goldman Sachs set a $31 target and a “buy,” Jefferies set a $25 target and a “buy,” and William Blair rated “outperform.” MarketBeat data show a consensus “Buy” and average target $26.67.

$NVDAMed

Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Broadcom, Microsoft, IBM, Meta, Tyson Foods & more

Wall Street analysts issued multiple calls Monday. Goldman initiated HawkEye 360 as buy; Morgan Stanley upgraded Dell to equal weight; Wells Fargo upgraded Tandem Diabetes Care to overweight. Citizens initiated Microsoft at Market Outperform with a $550 target; Barclays initiated IBM at overweight with a $350 target. Cantor reiterated Tesla overweight; RBC reiterated Meta outperform. Broadcom was reiterated overweight by Morgan Stanley, raising its target to $485.

$CLSKHigh

CleanSpark Sinks 6% Even as Bitcoin Jumps 7%, MARA Holds Flat as Traders Weigh Tensions Among AI Miners

CleanSpark (CLSK) fell 6% to $11.84, while MARA Holdings (MARA) was flat at $11.14, despite Bitcoin (BTC) rising 7% to $77,740.82. Investors are reassessing the miner-to-AI-landlord pivot, with CleanSpark's mining revenue down 30% and EBITDA deeply negative. Riot Platforms (RIOT) saw initial gains from a $9.1B AI deal fade. The CoinShares Valkyrie Bitcoin Miners ETF (WGMI) dropped 3%.

$DHRMedAI 8/10

Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?

Danaher (DHR) and Intuitive Surgical (ISRG) present contrasting growth paths. Danaher benefits from improving life sciences spending, with strong bioprocessing orders and $100M revenue shifted to next year. Intuitive Surgical reports 18% YoY growth in da Vinci system placements, 70% non-GAAP gross margin, and 85% recurring revenue. Investors must decide between cyclical recovery and structural growth.